Tonix Pharmaceuticals: Breakthrough Therapy Designation In PTSD
Edison | Jan 24, 2017 12:45AM ET
Tonix Pharm (NASDAQ:TNXP) has announced that it has been granted Breakthrough Therapy Designation (BTD) by the FDA as its Phase II AtEase data for TNX-102 SL in military-related PTSD indicate the drug may successfully treat a serious condition, a key requirement for BTD. Key benefits of BTD are intensive guidance from the FDA on the drug development program, an organizational commitment involving senior managers at the FDA, and the submission of portions of the NDA on a rolling basis.
Designation granted for all of PTSD
By granting BTD for the entire indication, the FDA may be signaling that it does not view military-related and civilian post-traumatic stress disorder (PTSD) as fundamentally different and hence only one application will be necessary. Currently, Tonix expects to start a second Phase III in predominantly civilian PTSD sufferers after the start of the HONOR study. While the FDA may not view military and civilian PTSD as different, the trial will likely be required to gain sufficient exposure in female PTSD sufferers.
To read the entire report Please click on the pdf File Below
Tonix Pharmaceuticals - Breakthrough Therapy Designation In PTSD
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.